{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:14:05Z","timestamp":1770725645755,"version":"3.49.0"},"reference-count":129,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Statins, originally developed as lipid-lowering agents, have effects that extend well beyond cholesterol. By altering inflammatory signaling, vascular tone, fibrogenesis, and immune regulation, they engage pathways that shape a wide range of gastrointestinal diseases. Human data now suggest that these biological actions carry clinical weight. In metabolic dysfunction-associated steatotic liver disease and its progressive form, metabolic dysfunction-associated steatohepatitis, alcohol-associated liver disease, and chronic viral hepatitis (HBV and HCV), statin exposure is safe and associated with slower disease progression, fewer episodes of decompensation, and lower incidence of hepatocellular carcinoma. Randomized studies in cirrhosis show reductions in portal pressure, with cohort data linking use to fewer variceal bleeds, ascites, and hepatic encephalopathy. In inflammatory bowel disease, large registries and pilot trials indicate reduced flares, lower corticosteroid requirements, and decreased need for surgery, with early biomarker evidence supporting an anti-inflammatory effect. Smaller studies hint at benefits in other gastrointestinal contexts, though the evidence remains fragmented. Across these populations, true hepatotoxicity is rare; risk of myopathy is modest and largely confined to advanced cirrhosis or drug\u2013drug interactions. Collectively, these findings support cautious repurposing of statins in gastroenterology and underline the need for definitive randomized trials to resolve class effects, optimize dose and duration, and identify reliable biomarkers of response.<\/jats:p>","DOI":"10.1097\/crd.0000000000001105","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:04:19Z","timestamp":1770653059000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Statins in Gastroenterology: Mechanisms, Human Evidence, and Safety"],"prefix":"10.1097","author":[{"given":"Assem","family":"Al Refaei","sequence":"first","affiliation":[{"name":"Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Basta","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Msinjili","sequence":"additional","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Lebovics","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatobiliary Diseases, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"R1-20260209","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2022.12138","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US preventive services task force.","volume":"328","author":"Chou","year":"2022","journal-title":"JAMA"},{"key":"R2-20260209","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system.","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"key":"R3-20260209","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00204-023-03492-6","article-title":"Understanding the molecular mechanisms of statin pleiotropic effects.","volume":"97","author":"German","year":"2023","journal-title":"Arch Toxicol"},{"key":"R4-20260209","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41564-023-01363-5","article-title":"Microbiota-derived tryptophan catabolites mediate the chemopreventive effects of statins on colorectal cancer.","volume":"8","author":"Han","year":"2023","journal-title":"Nat Microbiol"},{"key":"R5-20260209","doi-asserted-by":"crossref","first-page":"102300","DOI":"10.1016\/j.eclinm.2023.102300","article-title":"Association between statin use and the prognosis of hepatocellular carcinoma after resection: a nationwide cohort study.","volume":"65","author":"Jeon","year":"2023","journal-title":"eClinicalMedicine"},{"key":"R6-20260209","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izaf077","article-title":"Statin use is associated with a less severe disease course in inflammatory bowel disease: a Nationwide Cohort study 2006-2020.","author":"Khalili","year":"2025","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 4","key":"R7-20260209","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000174688","article-title":"Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.","volume":"77","author":"Alberts","year":"1990","journal-title":"Cardiology"},{"key":"R8-20260209","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1001\/jamainternmed.2022.0134","article-title":"Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of statin treatment: a systematic review and meta-analysis.","volume":"182","author":"Byrne","year":"2022","journal-title":"JAMA Intern Med"},{"key":"R9-20260209","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1874467209666160112123746","article-title":"Mevalonate cascade and its regulation in cholesterol metabolism in different tissues in health and disease.","volume":"10","author":"Hashemi","year":"2017","journal-title":"Curr Mol Pharmacol"},{"key":"R10-20260209","doi-asserted-by":"crossref","first-page":"e002474","DOI":"10.1136\/jitc-2021-002474","article-title":"Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer.","volume":"9","author":"Nam","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R11-20260209","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jpp\/rgae024","article-title":"Regulatory impact of statins on macrophage polarization: mechanistic and therapeutic implications.","volume":"76","author":"Sadeghi","year":"2024","journal-title":"J Pharm Pharmacol"},{"key":"R12-20260209","doi-asserted-by":"crossref","first-page":"115068","DOI":"10.1016\/j.intimp.2025.115068","article-title":"Lovastatin alleviates DSS-induced colitis by modulating macrophage polarization via the PPAR\u03b3-NF-\u03baB pathway.","volume":"161","author":"Zhu","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"R13-20260209","doi-asserted-by":"crossref","first-page":"e76538","DOI":"10.1371\/journal.pone.0076538","article-title":"Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis.","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"R14-20260209","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1136\/gutjnl-2014-308800","article-title":"Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension.","volume":"64","author":"Trebicka","year":"2015","journal-title":"Gut"},{"key":"R15-20260209","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10620-011-1879-4","article-title":"Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast\/myofibroblast apoptosis in the regeneration\/healing process from TNBS-induced colitis.","volume":"57","author":"Abe","year":"2012","journal-title":"Dig Dis Sci"},{"key":"R16-20260209","first-page":"777","article-title":"Effects of atorvastatin and ezetimibe on CD147, HIF-1, MMP-2 and VEGF in carotid atherosclerotic plaque under the guidance of IVUS.","volume":"37","author":"Xie","year":"2024","journal-title":"Pak J Pharm Sci"},{"key":"R17-20260209","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.atherosclerosis.2005.06.019","article-title":"Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells.","volume":"185","author":"H\u00f6lschermann","year":"2006","journal-title":"Atherosclerosis"},{"key":"R18-20260209","first-page":"1023","article-title":"Modulatory role of atorvastatin against high-fat diet and zymosan-induced activation of TLR2\/NF-\u0199B signaling pathway in C57BL\/6 mice.","volume":"24","author":"Arya","year":"2021","journal-title":"Iran J Basic Med Sci"},{"key":"R19-20260209","doi-asserted-by":"crossref","first-page":"9248","DOI":"10.3390\/ijms24119248","article-title":"MYD88 and proinflammatory chemokines in aortic atheromatosis: exploring novel statin effects.","volume":"24","author":"Mylonas","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R20-20260209","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.intimp.2006.10.013","article-title":"Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis.","volume":"7","author":"Lee","year":"2007","journal-title":"Int Immunopharmacol"},{"key":"R21-20260209","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.humimm.2005.04.004","article-title":"Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains.","volume":"66","author":"Kuipers","year":"2005","journal-title":"Hum Immunol"},{"key":"R22-20260209","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1136\/gutjnl-2019-318264","article-title":"Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling.","volume":"69","author":"Koelink","year":"2020","journal-title":"Gut"},{"key":"R23-20260209","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/eurheartj\/ehn138","article-title":"Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up.","volume":"29","author":"Guasti","year":"2008","journal-title":"Eur Heart J"},{"key":"R24-20260209","doi-asserted-by":"crossref","first-page":"116192","DOI":"10.1016\/j.biopha.2024.116192","article-title":"Advances in the molecular mechanisms of statins in regulating endothelial nitric oxide bioavailability: interlocking biology between eNOS activity and L-arginine metabolism.","volume":"171","author":"Chen","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"R25-20260209","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/gast.2000.8554","article-title":"Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension.","volume":"119","author":"Pateron","year":"2000","journal-title":"Gastroenterology"},{"key":"R26-20260209","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/10.shk.0000115756.74059.ce","article-title":"Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats.","volume":"21","author":"Giusti-Paiva","year":"2004","journal-title":"Shock"},{"key":"R27-20260209","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1046\/j.1523-1755.2000.00304.x","article-title":"Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects.","volume":"58","author":"Park","year":"2000","journal-title":"Kidney Int"},{"key":"R28-20260209","doi-asserted-by":"crossref","first-page":"13503","DOI":"10.1074\/jbc.M411859200","article-title":"Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts.","volume":"280","author":"Madonna","year":"2005","journal-title":"J Biol Chem"},{"key":"R29-20260209","doi-asserted-by":"crossref","first-page":"762506","DOI":"10.1155\/2015\/762506","article-title":"Statins increase the frequency of circulating CD4+ FOXP3+ regulatory T cells in healthy individuals.","volume":"2015","author":"Rodr\u00edguez-Perea","year":"2015","journal-title":"J Immunol Res"},{"key":"R30-20260209","doi-asserted-by":"crossref","first-page":"9010","DOI":"10.1038\/s41598-021-88489-w","article-title":"Ulcerative colitis immune cell landscapes and differentially expressed gene signatures determine novel regulators and predict clinical response to biologic therapy.","volume":"11","author":"Penrose","year":"2021","journal-title":"Sci Rep"},{"key":"R31-20260209","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s41467-021-22164-6","article-title":"Single-cell analyses of Crohn\u2019s disease tissues reveal intestinal intraepithelial T cells heterogeneity and altered subset distributions.","volume":"12","author":"Jaeger","year":"2021","journal-title":"Nat Commun"},{"key":"R32-20260209","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1038\/s41419-017-0010-y","article-title":"Increased apoptosis of regulatory T cells in patients with active autoimmune hepatitis.","volume":"8","author":"John","year":"2017","journal-title":"Cell Death Dis"},{"key":"R33-20260209","doi-asserted-by":"crossref","first-page":"e21491","DOI":"10.1097\/MD.0000000000021491","article-title":"Th17\/Treg imbalance in patients with severe acute pancreatitis: attenuated by high-volume hemofiltration treatment.","volume":"99","author":"Guo","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"R34-20260209","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1478-3231.2008.01682.x","article-title":"Atorvastatin induces apoptosis by a caspase-9-dependent pathway: an in vitro study on activated rat hepatic stellate cells.","volume":"28","author":"Aprigliano","year":"2008","journal-title":"Liver Int"},{"key":"R35-20260209","doi-asserted-by":"crossref","first-page":"166750","DOI":"10.1016\/j.bbadis.2023.166750","article-title":"Simvastatin inhibits hepatic stellate cells activation by regulating the ferroptosis signaling pathway.","volume":"1869","author":"Kitsugi","year":"2023","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"R36-20260209","doi-asserted-by":"crossref","first-page":"430","DOI":"10.20517\/cdr.2023.20","article-title":"Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells.","volume":"6","author":"Jansen","year":"2023","journal-title":"Cancer Drug Resist"},{"key":"R37-20260209","doi-asserted-by":"crossref","first-page":"e2626","DOI":"10.1038\/cddis.2016.472","article-title":"Simvastatin-induced cell cycle arrest through inhibition of STAT3\/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.","volume":"8","author":"Wang","year":"2017","journal-title":"Cell Death Dis"},{"key":"R38-20260209","doi-asserted-by":"crossref","first-page":"103320","DOI":"10.1016\/j.drudis.2022.07.005","article-title":"Statins and angiogenesis in non-cardiovascular diseases.","volume":"27","author":"Zahedipour","year":"2022","journal-title":"Drug Discov Today"},{"key":"R39-20260209","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2174\/156800905774932824","article-title":"Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy.","volume":"5","author":"Dulak","year":"2005","journal-title":"Curr Cancer Drug Targets"},{"key":"R40-20260209","doi-asserted-by":"crossref","first-page":"e00401","DOI":"10.1016\/j.heliyon.2017.e00401","article-title":"Statins decrease vascular epithelial growth factor expression via down-regulation of receptor for advanced glycation end-products.","volume":"3","author":"Tsujinaka","year":"2017","journal-title":"Heliyon"},{"key":"R41-20260209","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/cas.13570","article-title":"Activation of AMPK by simvastatin inhibited breast tumor angiogenesis via impeding HIF-1\u03b1-induced pro-angiogenic factor.","volume":"109","author":"Wang","year":"2018","journal-title":"Cancer Sci"},{"key":"R42-20260209","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/cvr\/cvs110","article-title":"Statin inhibits hypoxia-induced endothelin-1 via accelerated degradation of HIF-1\u03b1 in vascular smooth muscle cells.","volume":"95","author":"Hisada","year":"2012","journal-title":"Cardiovasc Res"},{"key":"R43-20260209","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1186\/s12885-020-07164-x","article-title":"Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer.","volume":"20","author":"G\u00f6bel","year":"2020","journal-title":"BMC Cancer"},{"key":"R44-20260209","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13046-021-02041-2","article-title":"Statins: a repurposed drug to fight cancer.","volume":"40","author":"Jiang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"R45-20260209","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4149\/neo_2013_032","article-title":"Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo.","volume":"60","author":"Liu","year":"2013","journal-title":"Neoplasma"},{"key":"R46-20260209","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/antiox13080906","article-title":"Altered mitochondrial function in MASLD: key features and promising therapeutic approaches.","volume":"13","author":"Radosavljevic","year":"2024","journal-title":"Antioxidants (Basel)"},{"key":"R47-20260209","doi-asserted-by":"crossref","first-page":"1390351","DOI":"10.3389\/fendo.2024.1390351","article-title":"The emerging role of oxidative stress in inflammatory bowel disease.","volume":"15","author":"Muro","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R48-20260209","doi-asserted-by":"crossref","first-page":"750731","DOI":"10.3389\/fmed.2021.750731","article-title":"Oxidative stress in intestinal ischemia-reperfusion.","volume":"8","author":"Li","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R49-20260209","doi-asserted-by":"crossref","first-page":"e2564","DOI":"10.1038\/cddis.2016.418","article-title":"Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.","volume":"8","author":"Henninger","year":"2017","journal-title":"Cell Death Dis"},{"key":"R50-20260209","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3390\/jcm11051313","article-title":"Antioxidant effects of statins by modulating Nrf2 and Nrf2\/HO-1 signaling in different diseases.","volume":"11","author":"Mansouri","year":"2022","journal-title":"J Clin Med"},{"key":"R51-20260209","doi-asserted-by":"crossref","first-page":"26714","DOI":"10.1074\/jbc.C500144200","article-title":"Statins exert endothelial atheroprotective effects via the KLF2 transcription factor*.","volume":"280","author":"Parmar","year":"2005","journal-title":"J Biol Chem"},{"key":"R52-20260209","doi-asserted-by":"crossref","first-page":"735573","DOI":"10.3389\/fphys.2021.735573","article-title":"The wHole story about fenestrations in LSEC.","volume":"12","author":"Szafranska","year":"2021","journal-title":"Front Physiol"},{"key":"R53-20260209","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.3390\/ijms26093988","article-title":"Liver sinusoidal endothelial cells in the regulation of immune responses and fibrosis in metabolic dysfunction-associated fatty liver disease.","volume":"26","author":"Puri","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R54-20260209","doi-asserted-by":"crossref","first-page":"103641","DOI":"10.1016\/j.ebiom.2021.103641","article-title":"Metallothionein 2 activation by pravastatin reinforces epithelial integrity and ameliorates radiation-induced enteropathy.","volume":"73","author":"Kwak","year":"2021","journal-title":"EBioMedicine"},{"key":"R55-20260209","doi-asserted-by":"crossref","first-page":"104392","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study.","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"key":"R56-20260209","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","article-title":"Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease.","volume":"73","author":"Zhou","year":"2024","journal-title":"Gut"},{"key":"R57-20260209","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamainternmed.2025.0115","article-title":"Statin use and risk of hepatocellular carcinoma and liver fibrosis in chronic liver disease.","volume":"185","author":"Choi","year":"2025","journal-title":"JAMA Intern Med"},{"key":"R58-20260209","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.14309\/ajg.0000000000001347","article-title":"Chemopreventive effect of statin on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis Cirrhosis.","volume":"116","author":"Pinyopornpanish","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R59-20260209","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MEG.0000000000002517","article-title":"Statin can reduce the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"35","author":"Zhang","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R60-20260209","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cgh.2023.04.017","article-title":"Statins are associated with a decreased risk of severe liver disease in individuals with noncirrhotic chronic liver disease.","volume":"22","author":"Sharma","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R61-20260209","doi-asserted-by":"crossref","first-page":"109096","DOI":"10.1016\/j.drugalcdep.2021.109096","article-title":"Statins and the risks of decompensated liver cirrhosis and hepatocellular carcinoma determined in patients with alcohol use disorder.","volume":"228","author":"Chiu","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"R62-20260209","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/apt.14243","article-title":"Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study.","volume":"46","author":"Bang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R63-20260209","doi-asserted-by":"crossref","first-page":"e0013","DOI":"10.1097\/HC9.0000000000000013","article-title":"Effects of statins and aspirin on HCC risk in alcohol-related cirrhosis: nationwide emulated trials.","volume":"7","author":"Kraglund","year":"2023","journal-title":"Hepatol Commun"},{"key":"R64-20260209","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ajg.2016.179","article-title":"Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a Nationwide Cohort Study.","volume":"111","author":"Huang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R65-20260209","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5152\/tjg.2020.19656","article-title":"Statins in hepatitis B or C patients is associated with reduced hepatocellular carcinoma risk: a systematic review and meta-analysis.","volume":"33","author":"Li","year":"2022","journal-title":"Turk J Gastroenterol"},{"key":"R66-20260209","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hep.28506","article-title":"Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.","volume":"64","author":"Simon","year":"2016","journal-title":"Hepatology"},{"key":"R67-20260209","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2015.07.006","article-title":"Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.","volume":"63","author":"Yang","year":"2015","journal-title":"J Hepatol"},{"key":"R68-20260209","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis.","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"key":"R69-20260209","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/ajg.2017.170","article-title":"Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis.","volume":"112","author":"Kamal","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R70-20260209","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"R71-20260209","doi-asserted-by":"crossref","first-page":"e030038","DOI":"10.1136\/bmjopen-2019-030038","article-title":"Systematic review with a meta-analysis: clinical effects of statins on the reduction of portal hypertension and variceal haemorrhage in cirrhotic patients.","volume":"9","author":"Wan","year":"2019","journal-title":"BMJ Open"},{"key":"R72-20260209","doi-asserted-by":"crossref","first-page":"e0332","DOI":"10.1097\/HC9.0000000000000332","article-title":"Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial.","volume":"7","author":"Kronborg","year":"2023","journal-title":"Hepatol Commun"},{"key":"R73-20260209","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis.","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"R74-20260209","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12876-019-1147-1","article-title":"Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis.","volume":"19","author":"Gu","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"R75-20260209","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/jgh.16495","article-title":"Statin use in cirrhosis and its association with incidence of portal vein thrombosis.","volume":"39","author":"Amjad","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"R76-20260209","doi-asserted-by":"crossref","first-page":"e2320222","DOI":"10.1001\/jamanetworkopen.2023.20222","article-title":"Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality.","volume":"6","author":"Vell","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R77-20260209","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cgh.2022.01.057","article-title":"Statin use and reduced hepatocellular carcinoma risk in patients with nonalcoholic fatty liver disease.","volume":"21","author":"Zou","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R78-20260209","doi-asserted-by":"crossref","first-page":"318","DOI":"10.7326\/M18-2753","article-title":"Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a Nationwide Swedish population.","volume":"171","author":"Simon","year":"2019","journal-title":"Ann Intern Med"},{"key":"R79-20260209","doi-asserted-by":"crossref","first-page":"5389044","DOI":"10.1155\/2022\/5389044","article-title":"A meta-analysis of statin use and risk of hepatocellular carcinoma.","volume":"2022","author":"Wang","year":"2022","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R80-20260209","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12885-021-07796-7","article-title":"Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma.","volume":"21","author":"Yang","year":"2021","journal-title":"BMC Cancer"},{"key":"R81-20260209","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12885-022-09192-1","article-title":"Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery.","volume":"22","author":"Khajeh","year":"2022","journal-title":"BMC Cancer"},{"key":"R82-20260209","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41598-018-38110-4","article-title":"Statin use is associated with decreased hepatocellular carcinoma recurrence in liver transplant patients.","volume":"9","author":"Cho","year":"2019","journal-title":"Sci Rep"},{"key":"R83-20260209","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/cancers16020249","article-title":"The impact of statins on the survival of patients with advanced hepatocellular carcinoma treated with Sorafenib or Lenvatinib.","volume":"16","author":"Han","year":"2024","journal-title":"Cancers"},{"key":"R84-20260209","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cgh.2012.12.036","article-title":"Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett\u2019s esophagus: a systematic review and meta-analysis.","volume":"11","author":"Singh","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R85-20260209","doi-asserted-by":"crossref","first-page":"e33359","DOI":"10.1097\/MD.0000000000033359","article-title":"The association between statin use and prognosis in esophageal cancer patients: a meta-analysis.","volume":"102","author":"Lv","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R86-20260209","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jss.2020.11.016","article-title":"Statins inhibit toll-like receptor 4-mediated growth of human esophageal adenocarcinoma cells.","volume":"260","author":"Gergen","year":"2021","journal-title":"J Surg Res"},{"key":"R87-20260209","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.3390\/jcm11237180","article-title":"Statins and the risk of gastric cancer: a systematic review and meta-analysis.","volume":"11","author":"Su","year":"2022","journal-title":"J Clin Med"},{"key":"R88-20260209","doi-asserted-by":"crossref","first-page":"e0146432","DOI":"10.1371\/journal.pone.0146432","article-title":"Statins attenuate Helicobacter pylori caga translocation and reduce incidence of gastric cancer: in vitro and population-based case-control studies.","volume":"11","author":"Lin","year":"2016","journal-title":"PLoS One"},{"key":"R89-20260209","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1158\/1940-6207.CAPR-09-0271","article-title":"Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.","volume":"3","author":"Bertagnolli","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"R90-20260209","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/jgh.13393","article-title":"Statin use and the risk of colorectal adenoma: a meta-analysis.","volume":"31","author":"Jung","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"R91-20260209","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s10620-009-0790-8","article-title":"For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes.","volume":"54","author":"Siddiqui","year":"2009","journal-title":"Dig Dis Sci"},{"key":"R92-20260209","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/jnci\/djr307","article-title":"Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.","volume":"103","author":"Ng","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R93-20260209","doi-asserted-by":"crossref","first-page":"101588","DOI":"10.1016\/j.clinre.2020.101588","article-title":"Statins use and the prognosis of colorectal cancer: a meta-analysis.","volume":"45","author":"Li","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R94-20260209","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12029-025-01238-4","article-title":"Statin use and pancreatic cancer: a meta-analysis of its association with incidence in the general population and survival in patients.","volume":"56","author":"Paul","year":"2025","journal-title":"J Gastrointest Cancer"},{"key":"R95-20260209","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.dld.2020.01.008","article-title":"Statin use improves survival in patients with pancreatic ductal adenocarcinoma: a meta-analysis.","volume":"52","author":"Tamburrino","year":"2020","journal-title":"Dig Liver Dis"},{"key":"R96-20260209","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2147\/IDR.S202346","article-title":"Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience.","volume":"12","author":"Metwally","year":"2019","journal-title":"Infect Drug Resist"},{"key":"R97-20260209","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/antibiotics10080965","article-title":"The role of statins on helicobacter pylori eradication: results from the European Registry on the management of H. pylori (Hp-EuReg).","volume":"10","author":"Caldas","year":"2021","journal-title":"Antibiotics"},{"key":"R98-20260209","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/bcpt.13343","article-title":"Interaction potential between clarithromycin and individual statins\u2014a systematic review.","volume":"126","author":"Hougaard Christensen","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R99-20260209","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/ibd.21822","article-title":"Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study.","volume":"18","author":"Crockett","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R100-20260209","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/bjp.2008.369","article-title":"Use of atorvastatin as an anti-inflammatory treatment in Crohn\u2019s disease.","volume":"155","author":"Grip","year":"2008","journal-title":"Br J Pharmacol"},{"key":"R101-20260209","doi-asserted-by":"crossref","first-page":"1490178","DOI":"10.3389\/fmed.2024.1490178","article-title":"Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: a randomized controlled pilot study.","volume":"11","author":"Alarfaj","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"R102-20260209","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1001\/jama.2009.1601","article-title":"Statin use and risk of gallstone disease followed by cholecystectomy.","volume":"302","author":"Bodmer","year":"2009","journal-title":"JAMA"},{"key":"R103-20260209","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/hepr.12433","article-title":"Statin use and risk of gallstone disease: a meta-analysis.","volume":"45","author":"Kan","year":"2015","journal-title":"Hepatol Res"},{"key":"R104-20260209","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/ph16040536","article-title":"Association between gallstone disease and statin use: a nested case\u2014control study in Korea.","volume":"16","author":"Kwon","year":"2023","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"R105-20260209","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2012.8439","article-title":"Lipid-modifying therapies and risk of pancreatitis: a meta-analysis.","volume":"308","author":"Preiss","year":"2012","journal-title":"JAMA"},{"key":"R106-20260209","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2036.2006.02728.x","article-title":"Statins and the risk of acute pancreatitis: a population-based case-control study.","volume":"23","author":"Thisted Horsdal","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R107-20260209","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.pan.2019.07.004","article-title":"Statin intake can decrease acute pancreatitis severit.","volume":"19","author":"Ruiz-Rebollo","year":"2019","journal-title":"Pancreatology"},{"key":"R108-20260209","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pan.2013.03.008","article-title":"Prior statin therapy is associated with milder course and better outcome in acute pancreatitis--a cohort study.","volume":"13","author":"Gornik","year":"2013","journal-title":"Pancreatology"},{"key":"R109-20260209","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/MEG.0000000000001060","article-title":"The relationship between the use of statins and mortality, severity, and pancreatic cancer in Danish patients with chronic pancreatitis.","volume":"30","author":"Bang","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R110-20260209","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ijc.32264","article-title":"Statins and pancreatic cancer risk in patients with chronic pancreatitis: a Danish nationwide population-based cohort study.","volume":"146","author":"Kirkeg\u00e5rd","year":"2020","journal-title":"Int J Cancer"},{"key":"R111-20260209","first-page":"OC13","article-title":"Early clinical experience with simvastatin for treating pain in patients with idiopathic chronic pancreatitis.","volume":"13","author":"Mehta","year":"2019","journal-title":"J Clin Diagn Res"},{"key":"R112-20260209","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1097\/MPA.0000000000001955","article-title":"A randomized, double-blinded, placebo-controlled trial of simvastatin to prevent recurrent pancreatitis.","volume":"51","author":"Goodman","year":"2022","journal-title":"Pancreas"},{"key":"R113-20260209","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury.","volume":"77","author":"Fontana","year":"2023","journal-title":"Hepatology"},{"key":"R114-20260209","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association.","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R115-20260209","first-page":"605","article-title":"Statins and liver injury.","volume":"9","author":"Thapar","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R116-20260209","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s10620-020-06630-7","article-title":"Safety of chronic simvastatin treatment in patients with decompensated cirrhosis: many adverse events but no liver injury.","volume":"66","author":"Mu\u00f1oz","year":"2021","journal-title":"Dig Dis Sci"},{"key":"R117-20260209","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/1744666X.2018.1440206","article-title":"Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations.","volume":"14","author":"Selva-O\u2019Callaghan","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"R118-20260209","doi-asserted-by":"crossref","first-page":"89","DOI":"10.17925\/EE.2022.18.2.89","article-title":"Statin-related muscle toxicity: an evidence-based review.","volume":"18","author":"Jeeyavudeen","year":"2022","journal-title":"TouchREV Endocrinol"},{"key":"R119-20260209","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOG.0000000000000716","article-title":"Statins for treatment of chronic liver disease.","volume":"37","author":"Marrache","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"key":"R120-20260209","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12876-021-01704-w","article-title":"A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis.","volume":"21","author":"Sung","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"R121-20260209","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association.","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"R122-20260209","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11883-020-00844-w","article-title":"Clinical pharmacology of statins: an update.","volume":"22","author":"Ferri","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"R123-20260209","first-page":"328","article-title":"HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview.","volume":"22","author":"Balasubramanian","year":"2021","journal-title":"Curr Drug Metab"},{"key":"R124-20260209","doi-asserted-by":"crossref","first-page":"108484","DOI":"10.1016\/j.jbc.2025.108484","article-title":"Cyclosporine a sterically inhibits statin transport by solute carrier OATP1B1.","volume":"301","author":"Sung","year":"2025","journal-title":"J Biol Chem"},{"key":"R125-20260209","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4066\/AMJ.2013.1616","article-title":"Life-threatening rhabdomyolysis following the interaction of two commonly prescribed medications.","volume":"6","author":"Fallah","year":"2013","journal-title":"Australas Med J"},{"key":"R126-20260209","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1345\/aph.1C467","article-title":"Simvastatin-fluconazole causing rhabdomyolysis.","volume":"37","author":"Shaukat","year":"2003","journal-title":"Ann Pharmacother"},{"key":"R127-20260209","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1524-6175.2005.05278.x","article-title":"Fibrates in combination with statins in the management of dyslipidemia.","volume":"8","author":"Jacobson","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R128-20260209","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/fcp.12959","article-title":"Exploring signals of myopathy associated with statin and contraindicated comedications in the realworld.","volume":"38","author":"Park","year":"2024","journal-title":"Fundam Clin Pharmacol"},{"key":"R129-20260209","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3389\/fmicb.2019.01947","article-title":"Alterations in gut microbiota by statin therapy and possible intermediate effects on hyperglycemia and hyperlipidemia.","volume":"10","author":"Kim","year":"2019","journal-title":"Front Microbiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:04:34Z","timestamp":1770653074000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":129,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001105","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}